Background: HER2 (human epidermal growth factor receptor 2) is present in 15%–25% of
breast cancers. Women with HER2-positive breast cancer usually have more aggressive …

Introduction About 20% of all mamma carcinomas are HER2 positive. The overexpression of
HER2 is considered to be a negative prognostic factor. Trastuzumab is a monoclonal anti …

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …

The emergence of trastuzumab has drastically changed therapy for breast cancer.
Trastuzumab (Herceptin; Genentech) is a recombinant humanized monoclonal antibody that …

OBJECTIVES:: To provide a review of the two pivotal clinical trials evaluating trastuzumab in
metastatic breast cancer, either in combination with chemotherapy or as a single agent …

Breast cancer patients who have HER2 gene amplification and, consequently, protein
overexpression, generally show an aggressive course with short disease-free and overall …

Background Trastuzumab is humanized monoclonal antibody targeting her 2 neu receptor,
overexpressed in 20% of breast cancers and part of the complex of Epidermal Growth Factor …

Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of
breast cancer tumors. It is associated with a more aggressive disease, higher recurrence …

Background We present the combined results of two trials that compared adjuvant
chemotherapy with or without concurrent trastuzumab in women with surgically removed …

Background Overexpression of the epidermal growth factor 2 HER2 in breast cancer tissue
is associated with shorter survival. Trastuzumab, a monoclonal antibody against HER2, can …